Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Amiodarone Stories

2014-02-13 08:30:36

NASDAQ: CRME TSX: COM VANCOUVER, Feb. 13, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced that a poster titled "Medical conversion with Vernakalant on postoperative cardio-surgical patients" by Thöne, M. et al., from the Department of Cardiovascular Surgery at the Heinrich-Heine-University Düsseldorf located in Düsseldorf, Germany, was presented at the 43(rd) Annual Meeting of the Germany Society for Thoracic and Cardiovascular Surgery...

2013-11-21 08:27:13

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 21, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that a publication titled, Pharmacological Cardioversion of Atrial Fibrillation with Vernakalant: Evidence in Support of the ESC Guidelines, was published in Europace, the official Journal of the European Heart Rhythm Association, and was made available in the advanced online article access section. The authors conclude that BRINAVESS is an efficacious...

2013-11-18 08:29:00

ChanRx Presents Study Results at 2013 American Heart Association Scientific Sessions DALLAS, Nov. 18, 2013 /PRNewswire/ -- ChanRx, a pharmaceutical company developing medicines for cardiovascular diseases, today announced positive safety and statistically significant efficacy data from a Phase IIb study of vanoxerine (GBR-12909), a drug in development for the treatment of atrial fibrillation. The data were presented yesterday at the American Heart Association 2013 Scientific...

2012-06-18 13:29:50

Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF. In most cases, AF can be treated successfully by an electrical cardioversion. Unfortunately, in the majority of patients, AF recurs during the first days or weeks after cardioversion. This is due to...

2011-07-21 07:00:00

RIDGEFIELD, Conn., July 21, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has been added to hospital formularies at 49 of the top 50 cardiology and heart surgery hospitals, as ranked by U.S. News & World Report's Best Hospitals 2011-2012, published online on July 19. PRADAXA is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and...

2011-07-11 20:23:31

There is no difference between brand-name and generic drug formulations of amiodarone "” taken to control arrhythmia "“ in the incidence of thyroid dysfunction, according to a study in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj101800.pdf. Amiodarone, prescribed to control irregular heartbeats, is known for causing hypo- and hyper-thyroidism. Amiodarone is available in Canada in brand-name formulations as well as less...

2011-05-19 07:00:00

RIDGEFIELD, Conn., May 19, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has received preferred Tier 2 formulary status with all AARP Medicare Part D plans through its pharmacy benefits manager, Prescription Solutions®. The AARP plans, which include AARP Medicare Rx and AARP MedicareComplete from Secure Horizons, provide prescription drug access to nearly 6.8...

2011-04-04 08:15:00

RIDGEFIELD, Conn., April 4, 2011 /PRNewswire/ -- Two new retrospective subanalyses of the RE-LY(R) trial, involving Pradaxa(R) (dabigatran etexilate mesylate) capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin (1) occurred irrespective of CHA2DS2-VASc risk score (2) and the type of non-valvular atrial fibrillation (NVAF) (permanent, persistent and paroxysmal)(3). The results were presented at the American College of Cardiology's 60th Annual...

2011-02-15 07:00:00

RIDGEFIELD, Conn., Feb. 15, 2011 /PRNewswire/ -- Pradaxa® (dabigatran etexilate mesylate) capsules is now recommended as an alternative to warfarin to reduce the risk of stroke and blood clots in patients with non-valvular atrial fibrillation (NVAF) in the Guidelines on the Management of Patients With Atrial Fibrillation, which were jointly developed by the American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and Heart Rhythm Society...

2011-01-05 07:00:00

RIDGEFIELD, Conn., Jan. 5, 2011 /PRNewswire/ -- Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to normal sinus rhythm, were published online on Jan. 3 in Circulation.(1) Stroke and systemic embolism and major bleeding episodes within 30 days of the cardioversion were the major outcome measures. The analysis reported that rates of...